Evidence map›Paper›PMID 35092022›Full record

ArticleEpilepsia2022

Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet.

Ellen Molteberg, Erik Taubøll, Magnhild Kverneland, Per Ole Iversen, Kaja Kristine Selmer, Karl Otto Nakken, Dag Hofoss, Per Medbøe Thorsby

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Prolonging Partial Remission in Type 1 Diabetes: The Role of Low-Carbohydrate Diet: A Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  6. Hormonal Changes in Women with Epilepsy.Neuropsychiatric disease and treatment · 2024
    Review
  7. Does a Ketogenic Diet Have a Place Within Diabetes Clinical Practice? Review of Current Evidence and Controversies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ellen MoltebergNational Center for Epilepsy, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-5716-8061
Erik TaubøllFaculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-7208-7932
Magnhild KvernelandNational Center for Epilepsy, Oslo University Hospital, Oslo, Norway.
Per Ole IversenFaculty of Medicine, University of Oslo, Oslo, Norway.
Kaja Kristine SelmerNational Center for Epilepsy, Oslo University Hospital, Oslo, Norway.
Karl Otto NakkenNational Center for Epilepsy, Oslo University Hospital, Oslo, Norway.
Dag HofossNational Center for Epilepsy, Oslo University Hospital, Oslo, Norway.
Per Medbøe ThorsbyHormone Laboratory, Department of Medical Biochemistry and Biochemical Endocrinology and Metabolism Research Group, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-9615-1035
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate whether the modified Atkins diet (MAD), a variant of the ketogenic diet, has an impact on bone- and calcium (Ca) metabolism.

methodsTwo groups of adult patients with pharmacoresistant epilepsy were investigated. One, the diet group (n = 53), was treated with MAD for 12 weeks, whereas the other, the reference group (n = 28), stayed on their habitual diet in the same period. All measurements were performed before and after the 12 weeks in both groups. We assessed bone health by measuring parathyroid hormone (PTH), Ca, 25-OH vitamin D (25-OH vit D), 1,25-OH vitamin D (1,25-OH vit D), phosphate, alkaline phosphatase (ALP), and the bone turnover markers procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide collagen type 1 (CTX-1). In addition, we examined the changes of sex hormones (estradiol, testosterone, luteinizing hormone, follicle-stimulating hormone), sex hormone-binding globulin, and leptin.

resultsAfter 12 weeks of MAD, we found a significant reduction in PTH, Ca, CTX-1, P1NP, 1,25-OH vit D, and leptin. There was a significant increase in 25-OH vit D. These changes were most pronounced among patients <37 years old, and in those patients with the highest body mass index (≥25.8 kg/m²), whereas sex and type of antiseizure medication had no impact on the results. For the reference group, the changes were nonsignificant for all the analyses. In addition, the changes in sex hormones were nonsignificant. SIGNIFICANCE: Twelve weeks of MAD treatment leads to significant changes in bone and Ca metabolism, with a possible negative effect on bone health as a result. A reduced level of leptin may be a triggering mechanism. The changes could be important for patients on MAD, and especially relevant for those patients who receive treatment with MAD at an early age before peak bone mass is reached.

Indexed as

Diet, High-Protein Low-CarbohydrateEpilepsyAdultBiomarkersCalciumGonadal Steroid HormonesHumansLeptinParathyroid HormoneVitamin DBiomarkersCalciumGonadal Steroid HormonesLeptinParathyroid HormoneVitamin Dantiseizure medicationsbone healthketogenic dietleptinsex hormones

Identifiers

PMID35092022
PMCPMC9304173
OpenAlexW4210619992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.